"Le Groupe Hospitalier Mutualiste de Grenoble est un Établissement de Santé Privé d'Intérêt Collectif (ESPIC) à but non lucratif participant au service public hospitalier. Il offre plus de 400 lits et places de médecine, chirurgie, maternité / obstétrique, urgences, cancérologie, soins de suite et de réadaptation situés au cœur de Grenoble. L'établissement est doté d'un plateau technique récent et performant et dispose de services transversaux reconnus (centre douleur, équipe mobile gériatrie, laboratoire...). L'établissement a satisfait sans réserve ni recommandation à la visite de certification V2014 en 2017. Institut de Cancérologie du GHM (Daniel Hollard) - Avec"

During the past decade, Institut Daniel Hollard conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 5 clinical trials were completed, i.e. on average, 45.5% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut Daniel Hollard" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Celgene" with 3 trials sponsored, "Centre Leon Berard" with 3 trials sponsored, "The Lymphoma Academic Research Organisation" with 3 trials sponsored and "UNICANCER" with 3 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut Daniel Hollard" #1 collaborator was "AbbVie" with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator, "Janssen-Cilag Ltd." with 2 trials as a collaborator and "Lymphoma Study Association" with 2 trials as a collaborator. Other collaborators include 10 different institutions and companies that were collaborators in the rest 20 trials.

According to Clinical.Site data, the most researched conditions in "Institut Daniel Hollard" are "Breast Cancer" (9 trials), "Lymphoma" (3 trials), "Multiple Myeloma" (3 trials), "Ovarian Cancer" (3 trials) and "Breast Carcinoma" (1 trials). Many other conditions were trialed in "Institut Daniel Hollard" in a lesser frequency.

Most popular intervention types in "Institut Daniel Hollard" are "Drug" (24 trials), "Biological" (6 trials), "Procedure" (5 trials), "Other" (4 trials) and "Genetic" (2 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (5 trials), "Bevacizumab" (4 trials), "Docetaxel" (4 trials), "Epirubicin" (4 trials) and "Trastuzumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Institut Daniel Hollard" are 19 trials for "All" genders and 13 trials for "Female" genders.

Currently, there are NaN active trials in "Institut Daniel Hollard". undefined are not yet recruiting, 5 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Institut Daniel Hollard, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Institut Daniel Hollard, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".